Clinical trials: Secondary Cancer
Metastatic Breast Cancer, Breast Cancer
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT06246968
- Testing
- Pembrolizumab, Cryoablation, Histotripsy
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oncology, Prostate Cancer
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
A [18]F-PSMA-1007 PET/CT or PET/MRI scan are nuclear medicine tests used to create pictures of the whole body that may show where cells that express Prostate-Specific Membrane Antigen (PSMA) are found.
- Trial name
- NCT05712174
- Testing
- [18]F-PSMA-1007
- Where
- Canada
- Volunteers
- 176 people
- Sponsor
- AHS Cancer Control Alberta
Breast Neoplasms, Breast Cancer
Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing
Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence.
- Conditions
- Breast Neoplasms, Breast Cancer, Left Sided Breast Cancer
- Trial name
- PERSBRA (NCT04929197)
- Testing
- PERSBRA
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Medical University Hospital
Gastroenteropancreatic Neuroendocrine Tumors
Community-based Neuroendocrine Tumor (NET) Research Study
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot.
- Trial name
- NCT02730104
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ipsen
Leukemia
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006084
- Testing
- lintuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Labor Stage, Second
Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma
Recent literature shows that birth injury is associated with postpartum pelvic floor dysfunction (pelvic organ prolapse and fecal and urinary incontinence).
- Trial name
- NCT03518684
- Testing
- Natalis
- Where
- Lebanon
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
Colorectal Cancer
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly.
- Trial name
- CORE 2 (NCT00479752)
- Testing
- FOLFOX4 (Oxaliplatin), Cetuximab
- Where
- 24 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 151 people
- Sponsor
- Central European Cooperative Oncology Group
Colorectal Cancer
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver metastases for patients with microsatellite stable…
- Trial name
- NCT03802747
- Testing
- Durvalumab, Durvalumab and Tremelimumab, Y-90 Selective Internal Radiation Therapy (SIRT)
- Sponsor
- University of Colorado, Denver
Brain Metastases, Adult
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometastases.
- Trial name
- HF-SRT (NCT04805255)
- Testing
- Hypofractionated Stereotactic Radiotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital
Chronic Kidney Disease, Secondary Hyperparathyroidism
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with…
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
- Trial name
- NCT01219855
- Testing
- Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- OPKO Health, Inc.
Lobular Metastatic Breast Cancer
89Zr-atezolizumab PET Scan and Lobular Breast Cancer
The exploratory single center feasibility ImaGelato study is conducted as an imaging side study to the Dutch GELATO trial (Assessing efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer).
- Trial name
- ImaGelato (NCT04222426)
- Testing
- 89Zr-atezolizumab PET scans
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- University Medical Center Groningen
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot phase II trial studies the effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with non-small cell lung cancer that has come back or stage IIIB-IV.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02581943
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without…
- Trial name
- C-CLASSIC (NCT04262635)
- Testing
- Cetuximab, Capecitabine, Cetuximab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
This phase II trial studies how well the combination of botensilimab, balstilimab and regorafenib works compared to botensilimab and balstilimab in treating patients with microsatellite stable colorectal cancer that may have…
- Conditions
- Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Metastatic Colon Adenocarcinoma
- Trial name
- NCT06575725
- Testing
- Balstilimab, Biopsy, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Breast Cancer
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00020176
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Malignant Metastatic Melanoma
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
- Conditions
- Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma
- Trial name
- NCT01212276
- Testing
- MORAb-028
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Morphotek
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006050
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- 3 sites in France
- Sponsor
- UNICANCER
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
- Trial name
- NCT04886804
- Testing
- zongertinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 554 people
- Sponsor
- Boehringer Ingelheim
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)